Novel Coronavirus Information Center

Elsevier’s free health and medical research on the novel coronavirus (SARS-CoV-2) and COVID-19

January 27, 2020 - Updated April 10, 2020
3D illustration of Coronavirus (©
3D illustration of Coronavirus (©

Welcome to Elsevier's Novel Coronavirus Information Center  Here you will find expert, curated information for the research and health community on SARS-CoV-2 (the novel coronavirus) and COVID-19 (the disease).

All resources are free to access and include guidelines for clinicians and patients.

For Researchers
Under the Research tab, you will find the latest early-stage and peer-reviewed research on COVID-19 from journals including The Lancet and Cell Press. We have also made more than 21,000 related articles free to access on ScienceDirect. These articles are also available to download with rights for full text and data mining, re-use and analyses for as long as needed.

View the 21,000+ free articles

Download full text for data mining
Username: public | Password: beat_corona (note: FTP client software/plugin needed to access download)

For Clinicians
Under the Clinical information tab, you will find evidence-based skill guides and care plans for treatment, safety and patient education, along with emergency prepared webinars by the CDC.

For Patients
In the Patient resources section, you can find our 3D4Medical coronavirus video, resources from the CDC and WHO, and information about Elsevier's Patient Access Program for research.

Share your feedback to help us improve our Novel Coronavirus Information Center


Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier

Recent events have shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products and a new R&D tool. We have also created an interactive global map of experts based on Scopus data.

Read more

Clinical information

New ventilator recommendations

Use and reuse of N95 respirators

Here is ECRI’s clinical evidence assessment on the use and reuse of N95 respirators and the ECRI COVID-19 Resource Center.

NEJM videos in clinical medicine procedures

NEJM has made a selection of procedural training videos to assist non-ICU clinical staff caring for critically ill patients. They are freely available for the during of the outbreak.

Use of PPE by anesthesia professionals

Joint statement on use of personal protective equipment from the American Society of Anesthesiologists (ASA), Anesthesia Patient Safety Foundation (APSF), American Academy of Anesthesiologist Assistants (AAAA) and American Association of Nurse Anesthetists (AANA).

Video: How Fangcang Shelter Hospitals function in combating COVID-19

With Chen Wang, MD, PhD, FCCP, President of the Chinese Academy of Medical Sciences | April 1, 2020

When Wuhan faced a surge of COVID-19 patients, they couldn’t all be admitted to hospitals, and high infection risk threatened the lives of health workers. That same situation is now occurring around the world.

Read more and watch the video

JACC: COVID-19 guidance for cardiovascular clinicians

As you work together on the front lines, the Journal of the American College of Cardiology (AJCC) journals and the American College of Cardiology (ACC) are providing COVID-19 clinical guidance for global cardiovascular clinicians. Here you can find recently accepted manuscripts and webinars from the American College of Cardiology.

New podcast series

Expert Insights on COVID-19 with Elsevier

Elsevier has created a new podcast series for frontline clinicians and providers. In this three-part series, experts share their insights into the mode of transmission and pathophysiology of the virus, how medical informatics and telemedicine are used to manage the pandemic, and best practices for emergency nursing crisis preparedness.

Listen to the podcasts

COVID-19 drug therapy — potential options

Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.

More drug therapy guidance

Elsevier Clinical Solutions

We've selected content from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education collections to share what we know to date about the novel coronavirus.

New: COVID-19 Clinical Toolkit

Freely available resources to help clinicians stay current on standardized, evidence-based practices for treating patients with COVID-19.

Clinical Overviews on ClinicalKey

Clinical Overviews are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops Clinical Overviews through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.

Clinical Skills for Nursing

Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:

Interprofessional Care Plans

These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.

Patient engagement resources

Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:

Key facts for clinicians

By Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier | Updated March 2, 2020

Background: In December, China notified the World Health Organization of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, now called SARS-CoV-2 (initially called 2019-nCoV).

Read more

中文资源 (Chinese-language resources)


Resources from Elsevier's Clinical Solutions team in China

Date Title Published by (CN) Published by (EN) Link
  Virology 病毒学
1月24日 新型冠状病毒国家科技资源服务系统。共享:
国家微生物科学数据中心和国家病原微生物资源库 National Microbiological Data Center;
National Pathogen Resource Collection Center

View more resources





3D4Medical 视频揭示新冠病毒从传播到入侵的全过程

3D4Medical的旗舰平台Complete Anatomy,是世界上最先进的解剖学平台。2019年注册用户超过了120万,有超过2500万的下载量,在160个国家的苹果、微软和谷歌的应用商店中被选为排名第一的医疗应用。






Because Google is not available in China and various other countries, we are offering a local version of the map, enabling you also to download the data.

View the interactive version on Baidu







Read more


In this section, you can find the following resources:

The Lancet Coronavirus Hub

To assist health workers and researchers working under difficult and dangerous conditions to bring this outbreak to a close, The Lancet created a Coronavirus hub page. This hub brings together new coronavirus content from The Lancet journals as it is published.

Cell Press Coronavirus Resource Hub

At Cell Press, we recognize the urgent need to quickly share information that can help us better understand the biology of the SARS-CoV-2 coronavirus (COVID-19) and produce a potential vaccine. On our Coronavirus Resource Hub, curated by members of our editorial team, you'll find our policies for submitting papers related to COVID-19, as well as content about the outbreak as it appears in Cell Press journals.

1Science Coronavirus Research Repository

1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It aims to include quality controlled academic and research documents in all disciplines and languages and from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals. The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.

COVID-19 Clinical Guidance for Global Cardiovascular Clinicians

JACC Journals and the ACC are working to provide COVID-19 clinical guidance for global cardiovascular clinicians. On this page you will find the recently accepted manuscripts that the JACC Journals’ Editors hope will best inform care decision-making

Content hubs from other publishers

Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | American College of Cardiology| Chongqing VIP Information. Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.

You can find all these publishers and more on LitCovid — the National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.

Articles in Elsevier journals

A selection of articles curated by our Clinical Solutions team

Below are articles curated by our Clinical Solutions team and directly relevant to Novel Coronavirus (COVID-19). In addition, Elsevier has made more than 21,000 coronavirus-related articles freely available for six months, commencing in February 2020. We are updating this section continually, and we've created categories to make it easier to browse.


View more categories

Research from all publishers

LitCovid is the  National Library of Medicine's curated hub of scientific literature about novel coronavirus. It currently provides access to more than 3,200 articles in PubMed and is being updated daily.

More published research

Research in JAMA, BMJ, NEJM and more curated by our experts

Book chapters

Early-stage research

Preprints on SSRN

Emerging and rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.

SSRN, Elsevier’s world-leading platform devoted to the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.

View more preprints

Research trends

COVID-19: Seeking reliable information amid uncertainty

By Ian Chuang, MD, Chief Medical Officer, Elsevier | February 18, 2020

Medicine is continuously evolving in terms of refining, revising and discovering new knowledge. This is heightened in importance and compressed in time frame during a crisis such as the current viral outbreak of the COVID-19.

Read more

Resources for drug discovery

Angiotensin-Converting Enzyme 2 and Anti-Hypertensives in COVID-19

Dr. Carl (Chip) Lavie of the John Ochsner Heart and Vascular Institute in New Orleans shares insights from his article appearing online-ahead-of-proof on March 30 in Mayo Clinic Proceedings, where he and his colleagues explore the safety and effects of anti-hypertensives in relation to patients with COVID-19. They note it is too early to make definitive decisions, but it appears anti-hypertensives may be have a preventive effect against lung damage during the course of the disease.

COVID-19 drug therapy — updated on April 3

Pharmacists in Elsevier's Clinical Solutions group write about potential treatment options for COVID-19. Read their paper.

New R&D tool to capture clinical trial data is free for researchers studying COVID-19

Elsevier has just launched Veridata Electronic Data Capture (EDC), which enables clinical researchers to capture clinical trial data in a secure environment. To assist researchers working to develop vaccines and other therapies for COVID-19, Elsevier has pledged to make Veridata EDC available for free. Interested clinical researchers can contact Elsevier customer support via e-mail at and apply for a demo account. Following the necessary compliance training, they will receive a free 12-month license. Read the press release

Drug information from Elsevier's R&D Solutions

Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we use those tools to generate information relevant to combating COVID-19:

Mayo Clinic Proceedings: Possible COVID-19 Pharmacotherapies and QTc/TdP Liability

The Mayo Clinic Proceedings journal has released a pre-proof of a new paper titled Possible COVID-19 Pharmacotherapies and QTc/TdP Liability. From the abstract: "As the COVID-19 global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the “off label” re-purposing of drugs such as hydroxychloroquine and lopinavir/ritonavir with the potential for unwanted QT interval prolongation, and a risk of drug induced sudden cardiac death. With the possibility that a significant proportion of the world’s population could receive soon COVID-19 pharmacotherapies with torsadogenic potential for therapy or post-exposure prophylaxis, this document serves to help healthcare providers mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk to personnel of COVID 19 exposure and conserving the limited supply of personal protective equipment. Read the paper

NEJM podcast: new research on possible treatments for Covid-19 (March 2020)

Dr. Eric Rubin, Editor-in-Chief of NEJM, and Dr. Lindsey Baden, Deputy Editor, talk about new research on possible treatments for Covid-19. Eric Rubin is the Editor-in-Chief of the Journal. Listen to the interview

Interactive map: global disease outbreak experts

This map represents the most active institutions researching disease outbreak and control. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications researching the coronavirus and related diseases such as SARS from 1996 to the present (Feb 6, 2020). We then used the resulting ~22,000 publications to identify the researchers and institutions that are working in these areas. The map shows the 500 most prolific global institutions, along with the 200 most prolific Chinese institutions by publication count.

Click on a pin to see more about the institution, the numbers of researchers and their publications. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.

Pure portal: Discover research collaborators and institutions globally

Use this Pure portal to discover novel coronavirus related research collaborators and institutions around the world. It uses Elsevier’s Natural Language Fingerprinting technology, scientific taxonomies and Scopus profiles and can be used to filter and find associated publications.

Additional information and examples

Public health

Here, you will find guidance and commentary from experts along with official guidance from major health organizations such as the CDC and WHO. For research on public health and related topics, see our Research section.

JAMA coronavirus (COVID-19) update — vaccines and immunity

JAMA JN Learning | March 25, 2020

As COVID-19 spreads globally, populations who survive their illness will become immune. Mayo Vaccine Research Group Director Gregory Poland, MD, discusses antibody responses, duration of immunity, vaccine candidates and prospects for using convalescent serum to passively immunize unexposed high-risk people.

The role of data sharing in battling COVID-19

Ian Chuang, MDIn techUK, Ian Chuang, MD, Chief Medical Officer at Elsevier, writes: "In these unprecedented times, technology’s ability to mine and analyse research and medical data and access digital data on a global scale can play a vital role in helping public health authorities, researchers and clinicians to contain and manage COVID-19’s rapid progression." Read his post

Complexities of epidemics

Thomas P. Erlinger, MD, MPH | VP, Clinical Analytics, Elsevier | March 18, 2020

As a former state epidemiologist, I will say that epidemics are — complex. The first complexity is that the definition of an epidemic typically references a “widespread” occurrence of a disease without a common definition of what “widespread” means. A single case of Ebola or Measles in an area that has not had any cases before would be considered an outbreak and more than a few cases in a region might be considered an epidemic, whereas in a typical season, a single case of the flu would not be considered an outbreak and a few cases in a region would not be considered an epidemic.

Read more

JAMA Network video: Coronavirus in Italy – Q&A with ICU Physician Maurizio Cecconi of Humanitas University (March 13, 2020)

Physicians in Lombardy, Italy, have been overwhelmed by COVID-19 patients requiring critical care. Based on an existing ECMO center network, they developed a network of ICUs to rapidly identify, triage and manage coronavirus-infected patients. In this interview with JAMA Editor-in-Chief Howard Bauchner, MD, Prof. Maurizio Cecconi of Humanitas University in Milan discusses the region’s approach to the surge, including clinical and supply management, health worker training and protection, and ventilation strategies. Watch the video

COVID-19 podcasts and webinars

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

JAMA Medical News Podcast: Coronavirus and Beyond: Responding to Biological Threats

The 2019 novel coronavirus outbreak exemplifies ongoing biothreats to global security, as each new threat tests principles of preparation and response at national, regional, and clinical levels. Tom Inglesby, MD, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, discusses biosecurity with Angel Desai, MD, JAMA Fishbein fellow. Listen to the interview

Podcast: How long could the coronavirus that causes COVID-19 be with us?

Prof. Rodney Rohde of the Texas State University College of Health Professions talks about the likelihood of this virus extending "beyond this season, beyond this year," per guidance from the CDC. Watch the podcast

6 of the most common coronavirus questions the media is asking

By Rodney E. Rohde, PhD, Professor and Chair, Clinical Laboratory Program, Texas State University | Feb 6, 2020

As an infectious disease and clinical microbiology expert, Prof. Rodney E. Rohde of the Texas State University College of Health Professions receives daily calls from the media, government and university officials, and public health and professional organizations asking him about the emerging novel coronavirus outbreak. In this article, he shares some of the most common questions and his responses.

Read more

More public health resources

Official coronavirus guidance from various countries:

Argentina | Australia | Canada | Chile | China | Colombia | France | Germany | Mexico | Peru | Singapore | Spain | UK | US

In the media

Patient resources

Video overview of Coronavirus from 3D4Medical — Watch now:

عدوى فيروس كورونا المستجد (patient education in Arabic)

عدوى فيروس كورونا المستجد

Elsevier's Patient Access Program for research

With our Patient Access Program, patients and their caregivers can receive medical or healthcare related research papers by emailing This email is constantly monitored by our support teams, who aim to provide individual articles at no cost to patients and caregivers within 24 hours. Requesters simply need to include the article title and authors, date published, and/or the DOI or URL if available so we can locate the article as quickly as possible. Learn more

COVID-19 podcasts and webinars

Relevant webinars and audio podcasts by subject matter experts compiled by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Each focuses on a different area of interest. View the list here

More resources

Videos from the World Health Organization

Usage notice

Since January 2020, Elsevier has created an online resource center with free information in English and Mandarin on the novel coronavirus (COVID-19).

This Novel Coronavirus Information Center is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource center — including this research content — immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource center remains active.


Written by

Elsevier Connect

Written by

Elsevier Connect

This site features daily stories for the global science, health and technology communities, written by experts in the field as well as Elsevier colleagues.